Radiation Toxicity - Pipeline Review, Q3 2011

Global Markets Direct, July 2011, Pages: 113

Radiation Toxicity - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Radiation Toxicity - Pipeline Review, Q3 2011', provides an overview of the Radiation Toxicity therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity. 'Radiation Toxicity - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Radiation Toxicity.
- A review of the Radiation Toxicity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Radiation Toxicity pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity pipeline depth and focus of Radiation Toxicity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Radiation Toxicity Overview
Therapeutics Development
An Overview of Pipeline Products for Radiation Toxicity
Radiation Toxicity Therapeutics under Development by Companies
Radiation Toxicity Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Radiation Toxicity Therapeutics - Products under Development by Companies
Radiation Toxicity Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Radiation Toxicity Therapeutics Development
Osiris Therapeutics, Inc.
Gamida Cell Ltd.
Nanotherapeutics, Inc.
Maxygen, Inc.
CEL-SCI Corporation
Aeolus Pharmaceuticals, Inc.
IR Biosciences Holdings, Inc.
Cleveland BioLabs, Inc.
Soligenix, Inc.
Cellerant Therapeutics, Inc.
Humanetics Corporation
Meabco A/S
Quigley Pharma, Inc.
Onconova Therapeutics, Inc
Exponential Biotherapies, Inc.
Bolder Biotechnology, Inc.
Canopus BioPharma Incorporated
Aton Pharma, Inc.
Neumedicines Inc.
Radiation Toxicity - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MAXY-G34 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prochymal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radilex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NanoDTPA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Multikine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEOL 10150 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGX201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protectan CBLB502 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGX-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ex-RAD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EA-230 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BP-C2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QR-336 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB700 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLT-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperbaric Oxygen Therapy + Radiation Therapy + Chemotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lovastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trental + Alfa Tocopherol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Amifostine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melatonin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine Trihydrate + Cisplatin + Etoposide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine Trihydrate + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ramosetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carboplatin + cisplatin + amifostine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amifostine trihydrate + cisplatin + etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine Trihydrate + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Palifermin + Cyclophosphamide + Etoposide + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mometasone Furoate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATON 004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HemaMax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDY-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enoxaparin + Pentoxifylline + Ursodeoxycholic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Toxicity Therapeutics – Drug Profile Updates
Radiation Toxicity - Featured News
May 31, 2011: Cleveland BioLabs Provides Update On CBLB502 And BARDA Development Contract
May 23, 2011: Cleveland BioLabs Receives Notice Of Patent Allowance From Japan For CBLB502
May 16, 2011: Cleveland BioLabs Receives New US Patent For CBLB502
May 03, 2011: Maxygen Submits Proposal To BARDA For Development Of MAXY-G34 For Acute Radiation Syndrome
Feb 22, 2011: Department of Health and Human Services Grants $4.5 Million To Research DSC127 In Skin Injuries Associated with Acute Radiation Exposure
Nov 30, 2010: Cleveland BioLabs Receives US Orphan Drug Status For CBLB502 For Treatment Of Exposure To Radiation
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants
Nov 02, 2010: Aeolus’ AEOL 10150 Promotes Survival In Non-Human Primates Exposed To Lethal Doses Of Radiation
Oct 19, 2010: Cleveland BioLabs Receives Chinese Notice Of Patent Allowance For CBLB502
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Radiation Toxicity, Q3 2011
Products under Development for Radiation Toxicity – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Osiris Therapeutics, Inc., 2011
Gamida Cell Ltd., 2011
Nanotherapeutics, Inc., 2011
Maxygen, Inc., 2011
CEL-SCI Corporation, 2011
Aeolus Pharmaceuticals, Inc., 2011
IR Biosciences Holdings, Inc., 2011
Cleveland BioLabs, Inc., 2011
Soligenix, Inc., 2011
Cellerant Therapeutics, Inc., 2011
Humanetics Corporation, 2011
Meabco A/S, 2011
Quigley Pharma, Inc., 2011
Onconova Therapeutics, Inc, 2011
Exponential Biotherapies, Inc., 2011
Bolder Biotechnology, Inc., 2011
Canopus BioPharma Incorporated, 2011
Aton Pharma, Inc., 2011
Neumedicines Inc., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Radiation Toxicity Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Radiation Toxicity, Q3 2011
Products under Development for Radiation Toxicity – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Customers who bought this item also bought

• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Marrow Transplantation – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013